ReviewBiotechnology journal2025
AI-Driven Quality Monitoring and Control in Stem Cell Cultures: A Comprehensive Review.
Review in Biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Cell-based therapies of autoimmune diseases in the context of artificial intelligence development.Clinical and experimental medicine · 2026Review
- Bridging the Gap in Cryopreservation: A Review of Cryoprotectant Innovation and Global Market Trends.Bioengineering (Basel, Switzerland) · 2026Review
- AI-Driven Innovations for Quality Control and Standardization: Future Strategies in Adipose-Derived Stem Cell Manufacturing.International journal of molecular sciences · 2026Review
- Orbital biomanufacturing: the key to space resiliency, operational persistence, and ethical sustainability.NPJ microgravity · 2026Review
- AI-Driven Quality Monitoring and Control in Stem Cell Cultures: A Comprehensive Review.Biotechnology journal · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advancements in stem cell research forge them into one of the most promising sources for cell therapy applications. Quality monitoring in stem cell culture is essential for ensuring consistency, viability, and therapeutic efficacy. Traditional methods involve periodic sampling for conducting endpoint assays such as cell viability, proliferation, and differentiation using microscopy and flow cytometry, which are labor-intensive and often lack the real-time monitoring of the processes for scale-up applications. This paper explores artificial intelligence (AI)-driven approaches for real-time quality control, integrating machine vision, predictive modeling, and sensor-based monitoring. AI models analyze high-resolution imaging and multi-sensor data to dynamically track critical quality attributes (CQAs), including cell morphology, proliferation rate, differentiation potential, environmental stability (pH, oxygen, and nutrient levels), genetic integrity, and contamination risks. These models enable automated anomaly detection, differentiation tracking, and adaptive culture optimization. By leveraging real-time feedback systems and multi-omics integration, AI-driven techniques enhance scalability, reproducibility, and process automation in stem cell biomanufacturing. This review outlines current advancements, challenges, and future directions in AI-assisted quality monitoring and highlights its potential to improve fully automated, scalable production of stem cell lines for clinical translation and regulatory compliance in regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.